CANNABIS NEWZ
The Wire / Regulation
REGULATIONPennsylvania

Four Pennsylvania Medical Cannabis Firms Sue DEA Over Rescheduling Supply-Chain Rules

Vertically integrated operators ask a federal appeals court to halt DEA registration requirements they say will block dispensaries from selling marijuana grown by their own cultivators.

The Cannabis Newz Automated Desk
Machine-written from our data · source: Marijuana Moment
November 20, 2026 · 2:04 PM ET
Wooden gavelFILE — enforcement · Auckland Museum / CC BY 4.0
Wooden gavel — file photo, not the scene of this story.

Four Pennsylvania medical marijuana companies have sued the Drug Enforcement Administration, arguing new registration requirements tied to federal rescheduling could cut off their dispensaries from cannabis grown by their own cultivation operations, according to Marijuana Moment.

The case, filed Thursday with the U.S. Court of Appeals for the District of Columbia Circuit, marks the second such lawsuit against DEA over the rescheduling rollout, Marijuana Moment reported, citing an earlier suit by other medical cannabis companies challenging the same restrictions.

The Companies and Their Claim

The petitioners are G.P.M.II, LLC, MLH Explorations LLC, Tri-Mountain Pure, LLC and Story of PA CR, LLC, all of which operate vertically integrated cultivation, processing and dispensary businesses in Pennsylvania, according to the outlet. They are asking the court to stay the DEA restrictions before they take effect.

What DEA Changed

Marijuana Moment reported that DEA last month granted federal registration and protections to hundreds of medical marijuana businesses as part of the rescheduling process, but also issued guidance requiring companies to source product only from, and sell only to, operators that have been registered or applied for registration within a specified window — with a compliance deadline of November 29.

The four companies say they applied within 60 days of the rescheduling order to register their dispensaries but did not seek registration for their manufacturing operations because of what their petition calls "inconsistent and confusing direction from DEA," as quoted by Marijuana Moment. As a result, they argue, their manufacturing divisions will be barred after November 29 from supplying any registered entity — including their own affiliated dispensaries.

The companies' attorneys wrote that the policy will "generate massive disruption by forcing early applicants (like Petitioners) to overhaul supply chains in a few short weeks, and shutting down facilities (like Petitioners' manufacturing divisions) that lack early-applicant status," according to the filing cited by Marijuana Moment. The petition adds that "patients who rely on medical marijuana to treat chronic and debilitating conditions will bear the cost."

Absent court intervention, the lawyers wrote, "the results will be devastating—for Petitioners' businesses and reputations, for the many individuals they employ, and for the countless patients they serve," per the reporting. The filing also states that the companies' manufacturing arms stand to lose what it describes as hundreds of thousands of dollars in monthly revenue from third-party sales, though the full financial breakdown was not detailed in the portion of the document reported by Marijuana Moment.

Market Context

State licensing records show Pennsylvania currently has 181 open medical marijuana retail locations, with the market still operating under medical-only status. The state database does not list separate counts for open cultivation, manufacturing or testing-lab licenses, nor year-to-date revenue figures, limiting the ability to independently assess how many Pennsylvania operators could be affected by the DEA's counterparty restrictions.

Related coverage in our database notes that more than half of Pennsylvania's medical dispensaries are operated by just six companies, underscoring the concentrated structure of a market where vertically integrated operators — like the four petitioners — play an outsized role.

What to Watch

The lawsuit lands amid broader change in Pennsylvania cannabis policy. Separate reporting from Marijuana Moment and other outlets in our database shows Democrats claimed a state Senate majority in the November elections, raising prospects for adult-use legalization legislation in 2027 — a development unrelated to the DEA dispute but part of a wider wave of regulatory activity touching the state's cannabis sector, including a pending bill on medical marijuana use by terminally ill hospital patients.

It remains unclear how the D.C. Circuit will rule on the requested stay or whether DEA will adjust its November 29 compliance deadline before the court acts. Marijuana Moment's reporting does not include a response from DEA to the new lawsuit, and the agency's rationale for the counterparty restrictions was not detailed in the available material.

Original report: Marijuana Moment ↗
Written by the Cannabis Newz automated newsroom, grounded in the cited news sources, our wire coverage, official license rosters and market filings — every fact is attributed and machine-checked against those sources before publication. Spotted an error? Tell us via your account page.